SPU-21 / Silo Pharma - LARVOL DELTA

Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent (GlobeNewswire) - "Silo Pharma...today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 16/825,371 titled 'Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and Disorders.' The new patent claims cover the Company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue....An estimated 1.3 million U.S. adults suffer from RA, the most common autoimmune disease in U.S. The U.S. market for RA drugs is expected to generate $63 billion by 2027."

Patent • Sales • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology